Related Experiment Videos
[Regression of left ventricular hypertrophy in obese hypertensive patients treated with diet and pharmacologic
F Barzizza1, L Magnani, G Crea
1I.R.C.C.S. Policlinico San Matteo, Belgioioso, Pavia.
Insights
Weight loss combined with captopril significantly improved cardiac structure in obese hypertensive patients. This combination therapy enhanced left ventricular mass reduction and atrial/ventricular dimensions compared to captopril alone.
Area of Science:
- Cardiology
- Hypertension Research
- Obesity Medicine
Context:
- Obesity and hypertension are significant risk factors for cardiovascular disease.
- Left ventricular hypertrophy (LVH) is a common complication in hypertensive patients.
- Captopril is a widely used angiotensin-converting enzyme inhibitor for hypertension management.
Purpose:
- To investigate the combined effect of captopril and hypocaloric diet on cardiac remodeling in obese hypertensive patients.
- To compare the efficacy of captopril monotherapy versus captopril plus diet in improving cardiovascular parameters.
Summary:
- Thirty-five obese hypertensive patients were divided into two groups: captopril alone (Group 1) and captopril plus hypocaloric diet (Group 2).
- After 6 months, Group 2 showed significant reductions in body weight and improved blood pressure control.
- Echocardiographic analysis revealed significant decreases in interventricular septal thickness, posterior wall thickness, and left ventricular mass in both groups, with greater reductions in Group 2.
- Group 2 also demonstrated significant reductions in left atrial and left ventricular diastolic dimensions, which were significantly greater than in Group 1.
Impact:
- Weight loss, in conjunction with captopril, offers superior benefits in reversing left ventricular hypertrophy in obese hypertensive individuals.
- The study suggests that weight reduction can mitigate volume overload, contributing to improved cardiac dimensions.
- Findings support integrated treatment strategies for managing complex cardiovascular risk in obese hypertensive patients.
Abstract:
Thirty-five obese (Body Mass Index: BMI > 30) hypertensive (diastolic blood pressure > 100 mmHg) patients were studied for 6 months. 18 patients (10 males, mean age 52 +/- 6 years) were treated with captopril 50 mg b.i.d. (Group 1); 17 patients, matched by age, sex and BMI were treated with captopril 50 mg b.i.d. and hypocaloric diet (Group 2). During follow-up a good control of blood pressure levels (< 150/90 mmHg) and a significant reduction in body weight (> 10%) were achieved in all patients of Group 2. Left heart anatomy was accessed by 2D guided M-mode echocardiogram before starting treatment and after 6 months. In Group 1 Interventricular Septal Thickness (ST), Posterior Wall Thickness (PWT) and Left Ventricular Mass (LVM) decreased significantly (p < 0.01). In Group 2 not only ST, PWT and LVM decreased significantly (p < 0.01 for ST and PWT, p < 0.001 for LVM), but also left atrial dimension (p < 0.05) and left ventricular diastolic dimension (p < 0.01). The percent reduction in AD, LVDD and LVM was significantly higher (p < 0.01) in Group 2. In obese hypertensives relevant weight loss can improve the effect of captopril treatment on left ventricular hypertrophy; the decrease of AD and LVDD is probably secondary to a reduction of the volume overload present in obese patients.